• English
  • 简体中文
Login Register
Current Location: Home > Drug Registration and Acceptance subscription Help
      -
      -
      -
        Visualized Analysis Export Evaluation Conclusion Evaluation Progress
        Show  
        Acceptance No. Drug Name Active Ingredient Dosage Form Classification Submission Acceptance Date Manufacturers Manufacturers Review Status Status Date View
        JYSZ2200038 依达赛珠单抗注射液 idarucizumab Injection Biological Products License Renew 2022-08-03 Boehringer Ingelheim (China) Investment Co Ltd;Boehringer Ingelheim International GmbH;Boehringer Ingelheim Pharma Gmbh & Co KG view
        JYSB2500040 依达赛珠单抗注射液 idarucizumab Injection Biological Products Supplementary Application 2025-02-18 Boehringer Ingelheim International GmbH;Boehringer Ingelheim Pharma Gmbh & Co KG view
        JYSB2101110 依达赛珠单抗注射液 idarucizumab Injection Biological Products Supplementary Application 2021-08-25 Boehringer Ingelheim International GmbH;Boehringer Ingelheim Pharma Gmbh & Co KG view
        JYSB2101218 依达赛珠单抗注射液 idarucizumab Injection Biological Products Supplementary Application 2021-12-31 Boehringer Ingelheim International GmbH;Boehringer Ingelheim Pharma Gmbh & Co KG view
        JYSB1800205 依达赛珠单抗注射液 idarucizumab Injection Biological Products Supplementary Application 2018-09-25 勃林格殷格翰(中国)投资有限公司 Boehringer Ingelheim (China) Investment Co Ltd;Boehringer Ingelheim International GmbH;Boehringer Ingelheim Pharma Gmbh & Co KG Filed 2018-09-28 view
        JYSB2000287 依达赛珠单抗注射液 idarucizumab Injection Biological Products Supplementary Application 2020-06-19 勃林格殷格翰(中国)投资有限公司 Boehringer Ingelheim (China) Investment Co Ltd;Boehringer Ingelheim International GmbH;Boehringer Ingelheim Pharma Gmbh & Co KG Filed 2020-06-22 view
        JYSB1900280 依达赛珠单抗注射液 idarucizumab Injection Biological Products Supplementary Application 2019-10-16 勃林格殷格翰(中国)投资有限公司 Boehringer Ingelheim (China) Investment Co Ltd;Boehringer Ingelheim International GmbH;Boehringer Ingelheim Pharma Gmbh & Co KG Certificate Issued 2020-09-27 view
        JYSB1800276 依达赛珠单抗注射液 idarucizumab Injection Biological Products Supplementary Application 2018-12-06 勃林格殷格翰(中国)投资有限公司 Boehringer Ingelheim (China) Investment Co Ltd;Boehringer Ingelheim International GmbH;Boehringer Ingelheim Pharma Gmbh & Co KG Filed 2018-12-13 view
        You can use the filter after selecting or entering the search conditions.
        Using filter may affect the loading speed.
        ×××××××××
        Contact usFeed-backServiceTop
        You can use the filter after selecting or entering the search conditions.
        Using filter may affect the loading speed.